Evidence map›Paper›PMID 42215833›Full record

ArticleDiscover oncology2026

High intratumoral CD8 positive T cell infiltration associated with pathologic complete response after neoadjuvant immunotherapy in locally advanced colon cancer.

Hiroki Okabayashi, Fuminori Teraishi, Ryohei Sumii, Koichi Okamoto, Tatsuya Toyokawa, Rika Omote, Ryusei Takahashi, Masashi Utsumi, Hideaki Miyaso, Masaru Inagaki

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Hiroki OkabayashiDepartment of Surgery, NHO Fukuyama Medical Center, Hiroshima, 720-8520, Japan.
Fuminori TeraishiDepartment of Surgery, NHO Fukuyama Medical Center, Hiroshima, 720-8520, Japan. pkc1940h@s.okayama-u.ac.jp.
Ryohei SumiiDepartment of Gastroenterology, NHO Fukuyama Medical Center, Hiroshima, Japan.
Koichi OkamotoDepartment of Gastroenterology, NHO Fukuyama Medical Center, Hiroshima, Japan.
Tatsuya ToyokawaDepartment of Gastroenterology, NHO Fukuyama Medical Center, Hiroshima, Japan.
Rika OmoteDepartment of Diagnostic Pathology, NHO Fukuyama Medical Center, Hiroshima, Japan.
Ryusei TakahashiDepartment of Surgery, NHO Fukuyama Medical Center, Hiroshima, 720-8520, Japan.
Masashi UtsumiDepartment of Surgery, NHO Fukuyama Medical Center, Hiroshima, 720-8520, Japan.
Hideaki MiyasoDepartment of Surgery, NHO Fukuyama Medical Center, Hiroshima, 720-8520, Japan.
Masaru InagakiDepartment of Surgery, NHO Fukuyama Medical Center, Hiroshima, 720-8520, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundNeoadjuvant immunotherapy has shown high pathological response rates in mismatch repair-deficient (dMMR) locally advanced colon cancer. However, clinically applicable predictors of response remain insufficiently defined. CASE PRESENTATION: We report three cases of patients with locally advanced mismatch repair-deficient (dMMR) colon cancer who received neoadjuvant immune checkpoint inhibitor (ICI) therapy (ipilimumab plus nivolumab or pembrolizumab) and subsequently underwent curative resection. All patients achieved a pathologic complete response (pCR). Pre-treatment biopsy specimens consistently demonstrated dense CD8

conclusionsThe findings of this case series support the feasibility and efficacy of neoadjuvant immunotherapy for locally advanced dMMR colon cancer. Dense CD8

Indexed as

CD8+ T-cell infiltrationLocally advanced colon cancerNeoadjuvant immunotherapyPathologic complete responseSurgery

Identifiers

PMID42215833
PMCPMC13424052

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.